A Study to Investigate the Safety of AB680 in Healthy Volunteers

Phase 1 Completed 64 enrolled Arcus Biosciences, Inc.

RandomizedSequentialQuadruple-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, single- and multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetic profile of AB680 in healthy volunteers.

Timeline

Start: 2018-10-16
Primary completion: 2019-08-19
Completion: 2019-08-19

Publications

Bowman CE, da Silva RG, Pham A, Young SW. An Exceptionally Potent Inhibitor of Human CD73. Biochemistry. 2019 Aug 6;58(31):3331-3334. doi: 10.1021/acs.biochem.9b00448. Epub 2019 Jul 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Quemliclustat	Small molecule	—	Intravenous

Indications

No indication recorded.